Protocol Ledger

NCT03488693 · Phase III · ACTIVE NOT RECRUITING

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Interventional Phase III clinical trial protocol NCT03488693 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-10-16 Enrollment: 2,138 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03488693
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)2,138 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03488693
Protocol FieldVerified Registry Value
NCT IdentifierNCT03488693
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment2,138 participants (ACTUAL)
Registered Start Date2018-10-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI